Shopping Cart 0
Cart Subtotal
AED 0

Autoinjectors Market Forecast up to 2024

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 18350

Details

Autoinjectors Market-Global Drivers, Restraints, Opportunities, Trends, and Forecast: 2018-2024

Overview: The medical devices that are primarily used for the self-injection of drugs, classically life-saving drugs, are known as autoinjectors. These devices are gaining increased importance for the management of anaphylaxis, diabetes, rheumatoid arthritis, multiple sclerosis, and others. Autoinjectors are relaxed to use and proposed for self-administration by individuals either at caretakers premises or at home.

Raising prevalence of serious medical conditions such as anaphylaxis & other food allergies, advancements in the autoinjectors technology, increasing demand for home healthcare, and the rising need for self-injectors are the factors aiding the growth of the autoinjectors market. Novel formulations of drugs and advancements in drug delivery systems along with favorable government regulations are providing an opportunity for the market growth. However, recent product recalls by the companies and the availability of substitutes for autoinjectors are hampering the market growth.

Market Analysis: The global autoinjectors market is estimated to witness a CAGR of 17.1% during the forecast period 2018-2024. The autoinjectors market is analyzed based on three segments-products, applications, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the autoinjectors market, followed by Europe, Asia Pacific, and Rest of the World. More than 65% of the market is occupied by North America, with the US being the major contributor to the market growth.

Product Analysis: Based on the products, the market is segmented into disposable autoinjectors and reusable autoinjectors. Disposable autoinjectors hold dominant market share and is also the fastest growing segment in the market.

Application Analysis: Based on the application areas, the market is segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis, diabetes, and others. The market is dominated by anaphylaxis owing to a high prevalence rate globally. The fastest growing segment of the market is rheumatoid arthritis due to increased development of novel drugs for the treatment of the condition.

Key Players: The major players in the market are Mylan NV, Novartis AG, Amgen, Inc., Becton Dickinson and Company, Bayer AG, and Eli Lilly & Company Ltd. The other key players in the market include Ypsomed Holding AG, Biogen Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical, Antares Pharma, Inc., Johnson and Johnson, and AbbVie, Inc.

Competitive Analysis: The key manufacturers of autoinjectors are concentrating on innovative marketing tactics to expand the reach of their products globally. Increasing awareness campaigns and price reduction of branded devices are among the strategies used by the leading companies to manage intense competition in the market. Many companies are rebranding their autoinjectors with worthwhile reductions in the price. In December 2016, Mylan launched the generic version of EpiPen to provide autoinjector for customers at lesser prices. This approach ought to help the company in targeting a larger customer pool, thus increasing the company's customer base in recent years.

Benefits: The report provides complete details about the usage and adoption rate of autoinjectors in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

 

READ MORE

Table Of Content

Scope

Table of Contents

1 Industry Outlook 9

1.1 Industry Overview 9

1.2 Total Addressable Market 10

2 Report Outline 13

2.1 Report Scope 13

2.2 Report Summary 13

2.3 Research Methodology 14

2.4 Report Assumptions 14

3 Market Snapshot 16

3.1 Market Definition-Infoholic Research 16

3.2 Segmented Addressable Market 16

3.3 Industry Trends 17

3.4 Related Markets 18

3.4.1 Transdermal Drug Delivery 18

3.4.1.1 Trends of cardiovascular drugs market 19

3.4.2 Pulmonary Drug Delivery Systems (PDDS) 19

3.4.3 Insulin Pumps 20

4 Market Outlook 22

4.1 Cost comparison of EpiPen and its Alternatives 22

4.2 Market Segmentation 22

4.3 Porter 5(Five) Forces 23

4.4 PEST Analysis 25

5 Market Characteristics 26

5.1 Market Dynamics 26

5.1.1 Drivers 26

5.1.1.1 Increasing prevalence of Anaphylaxis 26

5.1.1.2 Rising incidence of chronic disease 27

5.1.1.3 Increased Development Biologics / Biosimilars 28

5.1.1.4 Growing demand for home care 28

5.1.2 Opportunities 28

5.1.2.1 Increase in healthcare spending 28

5.1.2.2 Opportunities in emerging market 29

5.1.2.3 Favorable government policies 29

5.1.3 Restraints 30

5.1.3.1 Competition among major vendors 30

5.1.3.2 Increased product recall 30

5.1.3.3 High product pricing 30

5.2 DRO-Impact Analysis 31

5.3 Key Stakeholders 32

6 Application: Market Size and Analysis 33

6.1 Overview 33

6.2 Anaphylaxis 34

6.3 Multiple Sclerosis 35

6.4 Rheumatoid Arthritis 36

6.5 Diabetes 37

6.6 Others 38

7 Product Type: Market Size and Analysis 40

7.1 Overview 40

7.2 Disposable autoinjector 40

7.3 Reusable autoinjectors 41

8 Regions: Market Size and Analysis 43

8.1 Overview 43

8.2 North America 44

8.2.1 Overview 44

8.3 Europe 45

8.3.1 Overview 45

8.4 Asia Pacific 46

8.4.1 Overview 46

8.5 Rest of the World 48

8.5.1 Overview 48

9 Competitive Landscape 49

10 Vendors Profile 51

10.1 Amgen Inc. 51

10.1.1 Overview 51

10.1.2 Geographic Presence 54

10.1.3 Business Focus 55

10.1.4 SWOT Analysis 56

10.1.5 Business Strategies 57

10.2 Becton Dickinson and Company 57

10.2.1 Overview 57

10.2.2 Business Units 60

10.2.3 Geographic Revenue 61

10.2.4 Business Focus 61

10.2.5 SWOT Analysis 61

10.2.6 Business Strategies 62

10.3 Mylan N.V. 62

10.3.1 Overview 62

10.3.2 Business Segments 64

10.3.3 Geographic Presence 66

10.3.4 Business Focus 66

10.3.5 SWOT Analysis 66

10.3.6 Business Strategies 67

10.4 Bayer AG 67

10.4.1 Overview 67

10.4.2 Business Units 69

10.4.3 Geographic Presence 70

10.4.4 Business Focus 71

10.4.5 SWOT Analysis 71

10.4.6 Business Strategies 72

10.5 Eli Lilly & Company Ltd. 72

10.5.1 Overview 72

10.5.2 Business Units 74

10.5.3 Geographic Revenue 75

10.5.4 Business Focus 75

10.5.5 SWOT Analysis 75

10.5.6 Business Strategies 76

10.6 Novartis AG 76

10.6.1 Overview 76

10.6.2 Business Units 80

10.6.3 Geographic Presence 80

10.6.4 Business Focus 81

10.6.5 SWOT Analysis 81

10.6.6 Business Strategies 82

1 Vendors Profile 83

1.1 Ypsomed Holding AG 83

1.1.1 Overview 83

1.2 Biogen Pharmaceuticals 84

1.2.1 Overview 84

1.3 Pfizer Inc. 85

1.3.1 Overview 85

1.3.2 Highlights 87

1.4 Teva Pharmaceutical Industries Ltd. 87

1.4.1 Overview 87

1.5 Antares Pharma, Inc. 89

1.5.1 Overview 89

1.6 Johnson & Johnson 90

1.6.1 Overview 90

1.7 AbbVie Inc. 91

1.7.1 Overview 91

2 Annexure 94

Abbreviations 94

?


List Of Figure

Charts

 

CHART 1 RESEARCH METHODOLOGY OF GLOBAL AUTOINJECTOR MARKET 15

CHART 2 GLOBAL AUTOINJECTORS MARKET REVENUE, 2017-2024 (USD MILLION) 18

CHART 3 SEGMENTATION OF GLOBAL AUTOINJECTOR MARKET 23

CHART 4 PORTER 5 FORCES OF GLOBAL AUTOINJECTOR MARKET 24

CHART 5 PEST ANALYSIS OF AUTOINJECTOR MARKET 26

CHART 6 MARKET DYNAMICS-DRO ANALYSIS 27

CHART 7 DRO-IMPACT ANALYSIS OF GLOBAL AUTOINJECTORS MARKET 32

CHART 8 KEY STAKEHOLDERS 33

CHART 9 AUTOINJECTOR MARKET SEGMENT REVENUE BY APPLICATION, 2017 VS 2024 (USD MILLION) 34

CHART 10 ANAPHYLAXIS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 (USD MILLION) 36

CHART 11 MULTIPLE SCLEROSIS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 (USD MILLION) 36

CHART 12 RHEUMATOID ARTHRITIS MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 (USD MILLION) 37

CHART 13 DIABETES AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 (USD MILLION) 39

CHART 14 OTHERS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION, 2017-2024 (USD MILLION) 40

CHART 15 AUTOINJECTOS MARKET SEGMENT SHARE BY TYPE SEGMENTATION, 2017 (%) 41

CHART 16 DISPOSSABLE AUTOINJECTOR MARKET REVENUE, 2017-2024 (USD MILLION) 42

CHART 17 REUSABLE AUTOINJECTORS MARKET REVENUE, 2017-2024 (USD MILLION) 43

CHART 18 AUTOINJECTOR MARKET BY REGIONAL SEGMENTATION, 2017 (%) 44

CHART 19 AUTOINJECTORS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 46

CHART 20 AUTOINJECTOR MARKET REVENUE IN EUROPE, 2017-2024 (USD MILLION) 47

CHART 21 AUTOINJECTORS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 (USD MILLION) 48

CHART 22 AUTO INJECTOR MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 49

CHART 23 AMGEN INC.: OVERVIEW SNAPSHOT 54

CHART 24 AMGEN INC.: GEOGRAPHIC PRESENCE 55

CHART 25 AMGEN INC.: SWOT ANALYSIS 57

CHART 26 BECTON DICKINSON AND COMPANY: OVERVIEW SNAPSHOT 60

CHART 27 BECTON DICKINSON AND COMPANY: BUSINESS UNITS 61

CHART 28 BECTON DICKINSON AND COMPANY: GEOGRAPHIC REVENUE 62

CHART 29 BECTON DICKINSON AND COMPANY: SWOT ANALYSIS 62

CHART 30 MYLAN N.V.: OVERVIEW SNAPSHOT 64

CHART 31 MYLAN N.V.: BUSINESS SEGMENTS 65

CHART 32 MYLAN N.V.: GEOGRAPHIC PRESENCE 67

CHART 33 MYLAN N.V.: SWOT ANALYSIS 67

CHART 34 BAYER AG: OVERVIEW SNAPSHOT 69

CHART 35 BAYER AG: BUSINESS UNITS 70

CHART 36 BAYER AG: GEOGRAPHICAL PRESENCE 71

CHART 37 BAYER AG: SWOT ANALYSIS 72

CHART 38 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 74

CHART 39 ELI LILLY & COMPANY LTD.: BUSINESS UNITS 75

CHART 40 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE 76

CHART 41 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS 76

CHART 42 NOVARTIS AG: OVERVIEW SNAPSHOT 78

CHART 43 NOVARTIS AG: BUSINESS UNITS 81

CHART 44 NOVARTIS AG: GEOGRAPHIC PRESENCE 81

CHART 45 NOVARTIS AG: SWOT ANALYSIS 82

 


List Of Table

Tables

 

TABLE 1 AUTOINJECTOR MARKET REVENUE BY APPLICATION SEGMENTATION, 2017-2024 (USD MILLION) 33

TABLE 2 PREVALENCE OF DIABETES POPULATION FORECASTING BY REGION 37

TABLE 3 AUTOINJECTOR MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 44

TABLE 4 AMGEN INC.: OFFERINGS 51

TABLE 5 AMGEN INC.: RECENT DEVELOPMENTS 51

TABLE 6 BECTON DICKINSON AND COMPANY: OFFERINGS 58

TABLE 7 BECTON DICKINSON AND COMPANY: RECENT DEVELOPMENTS 58

TABLE 1 MYLAN N.V.: OFFERINGS 63

TABLE 2 MYLAN N.V.: RECENT DEVELOPMENTS 63

TABLE 3 BAYER AG: OFFERINGS 68

TABLE 4 BAYER AG: RECENT DEVELOPMENTS 68

TABLE 5 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 72

TABLE 6 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 73

TABLE 7 NOVARTIS AG: OFFERINGS 77

TABLE 8 NOVARTIS AG: RECENT DEVELOPMENTS 78

TABLE 9 YPSOMED HOLDING AG: SNAPSHOT 83

TABLE 10 YPSOMED HOLDING AG: RECENT DEVELOPMENTS 83

TABLE 11 BIOGEN PHARMACEUTICALS: OVERVIEW 84

TABLE 12 BIOGEN PHARMACEUTICALS: RECENT DEVELOPMENTS 84

TABLE 13 PFIZER INC. OVERVIEW 85

TABLE 14 PFIZER INC.: RECENT DEVELOPMENTS 86

TABLE 15 TEVA PHARMACEUTICAL INDUSTRIES LTD. OVERVIEW 87

TABLE 16 TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS 88

TABLE 17 ANTARES PHARMA, INC.: OVERVIEW 89

TABLE 18 ANTARES PHARMA, INC.: RECENT DEVELOPMENTS 89

TABLE 19 JOHNSON & JOHNSON: OVERVIEW 90

TABLE 20 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 90

TABLE 21 ABBVIE INC.: OVERVIEW 91

TABLE 22 ABBVIE INC.: RECENT DEVELOPMENTS 92

 

 

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Mylan NV

Novartis AG

Amgen, Inc.

Becton Dickinson and Company

Bayer AG

Eli Lilly & Company Ltd Ypsomed Holding AG, Biogen Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical, Antares Pharma, Inc., Johnson and Johnson, and AbbVie Inc

Company Profile

Company Profile Title

Autoinjectors Market-Global Drivers, Restraints, Opportunities, Trends, and Forecast: 2018-2024

Overview: The medical devices that are primarily used for the self-injection of drugs, classically life-saving drugs, are known as autoinjectors. These devices are gaining increased importance for the management of anaphylaxis, diabetes, rheumatoid arthritis, multiple sclerosis, and others. Autoinjectors are relaxed to use and proposed for self-administration by individuals either at caretakers premises or at home.

Raising prevalence of serious medical conditions such as anaphylaxis & other food allergies, advancements in the autoinjectors technology, increasing demand for home healthcare, and the rising need for self-injectors are the factors aiding the growth of the autoinjectors market. Novel formulations of drugs and advancements in drug delivery systems along with favorable government regulations are providing an opportunity for the market growth. However, recent product recalls by the companies and the availability of substitutes for autoinjectors are hampering the market growth.

Market Analysis: The global autoinjectors market is estimated to witness a CAGR of 17.1% during the forecast period 2018-2024. The autoinjectors market is analyzed based on three segments-products, applications, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the autoinjectors market, followed by Europe, Asia Pacific, and Rest of the World. More than 65% of the market is occupied by North America, with the US being the major contributor to the market growth.

Product Analysis: Based on the products, the market is segmented into disposable autoinjectors and reusable autoinjectors. Disposable autoinjectors hold dominant market share and is also the fastest growing segment in the market.

Application Analysis: Based on the application areas, the market is segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis, diabetes, and others. The market is dominated by anaphylaxis owing to a high prevalence rate globally. The fastest growing segment of the market is rheumatoid arthritis due to increased development of novel drugs for the treatment of the condition.

Key Players: The major players in the market are Mylan NV, Novartis AG, Amgen, Inc., Becton Dickinson and Company, Bayer AG, and Eli Lilly & Company Ltd. The other key players in the market include Ypsomed Holding AG, Biogen Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical, Antares Pharma, Inc., Johnson and Johnson, and AbbVie, Inc.

Competitive Analysis: The key manufacturers of autoinjectors are concentrating on innovative marketing tactics to expand the reach of their products globally. Increasing awareness campaigns and price reduction of branded devices are among the strategies used by the leading companies to manage intense competition in the market. Many companies are rebranding their autoinjectors with worthwhile reductions in the price. In December 2016, Mylan launched the generic version of EpiPen to provide autoinjector for customers at lesser prices. This approach ought to help the company in targeting a larger customer pool, thus increasing the company's customer base in recent years.

Benefits: The report provides complete details about the usage and adoption rate of autoinjectors in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

 

READ MORE

Scope

Table of Contents

1 Industry Outlook 9

1.1 Industry Overview 9

1.2 Total Addressable Market 10

2 Report Outline 13

2.1 Report Scope 13

2.2 Report Summary 13

2.3 Research Methodology 14

2.4 Report Assumptions 14

3 Market Snapshot 16

3.1 Market Definition-Infoholic Research 16

3.2 Segmented Addressable Market 16

3.3 Industry Trends 17

3.4 Related Markets 18

3.4.1 Transdermal Drug Delivery 18

3.4.1.1 Trends of cardiovascular drugs market 19

3.4.2 Pulmonary Drug Delivery Systems (PDDS) 19

3.4.3 Insulin Pumps 20

4 Market Outlook 22

4.1 Cost comparison of EpiPen and its Alternatives 22

4.2 Market Segmentation 22

4.3 Porter 5(Five) Forces 23

4.4 PEST Analysis 25

5 Market Characteristics 26

5.1 Market Dynamics 26

5.1.1 Drivers 26

5.1.1.1 Increasing prevalence of Anaphylaxis 26

5.1.1.2 Rising incidence of chronic disease 27

5.1.1.3 Increased Development Biologics / Biosimilars 28

5.1.1.4 Growing demand for home care 28

5.1.2 Opportunities 28

5.1.2.1 Increase in healthcare spending 28

5.1.2.2 Opportunities in emerging market 29

5.1.2.3 Favorable government policies 29

5.1.3 Restraints 30

5.1.3.1 Competition among major vendors 30

5.1.3.2 Increased product recall 30

5.1.3.3 High product pricing 30

5.2 DRO-Impact Analysis 31

5.3 Key Stakeholders 32

6 Application: Market Size and Analysis 33

6.1 Overview 33

6.2 Anaphylaxis 34

6.3 Multiple Sclerosis 35

6.4 Rheumatoid Arthritis 36

6.5 Diabetes 37

6.6 Others 38

7 Product Type: Market Size and Analysis 40

7.1 Overview 40

7.2 Disposable autoinjector 40

7.3 Reusable autoinjectors 41

8 Regions: Market Size and Analysis 43

8.1 Overview 43

8.2 North America 44

8.2.1 Overview 44

8.3 Europe 45

8.3.1 Overview 45

8.4 Asia Pacific 46

8.4.1 Overview 46

8.5 Rest of the World 48

8.5.1 Overview 48

9 Competitive Landscape 49

10 Vendors Profile 51

10.1 Amgen Inc. 51

10.1.1 Overview 51

10.1.2 Geographic Presence 54

10.1.3 Business Focus 55

10.1.4 SWOT Analysis 56

10.1.5 Business Strategies 57

10.2 Becton Dickinson and Company 57

10.2.1 Overview 57

10.2.2 Business Units 60

10.2.3 Geographic Revenue 61

10.2.4 Business Focus 61

10.2.5 SWOT Analysis 61

10.2.6 Business Strategies 62

10.3 Mylan N.V. 62

10.3.1 Overview 62

10.3.2 Business Segments 64

10.3.3 Geographic Presence 66

10.3.4 Business Focus 66

10.3.5 SWOT Analysis 66

10.3.6 Business Strategies 67

10.4 Bayer AG 67

10.4.1 Overview 67

10.4.2 Business Units 69

10.4.3 Geographic Presence 70

10.4.4 Business Focus 71

10.4.5 SWOT Analysis 71

10.4.6 Business Strategies 72

10.5 Eli Lilly & Company Ltd. 72

10.5.1 Overview 72

10.5.2 Business Units 74

10.5.3 Geographic Revenue 75

10.5.4 Business Focus 75

10.5.5 SWOT Analysis 75

10.5.6 Business Strategies 76

10.6 Novartis AG 76

10.6.1 Overview 76

10.6.2 Business Units 80

10.6.3 Geographic Presence 80

10.6.4 Business Focus 81

10.6.5 SWOT Analysis 81

10.6.6 Business Strategies 82

1 Vendors Profile 83

1.1 Ypsomed Holding AG 83

1.1.1 Overview 83

1.2 Biogen Pharmaceuticals 84

1.2.1 Overview 84

1.3 Pfizer Inc. 85

1.3.1 Overview 85

1.3.2 Highlights 87

1.4 Teva Pharmaceutical Industries Ltd. 87

1.4.1 Overview 87

1.5 Antares Pharma, Inc. 89

1.5.1 Overview 89

1.6 Johnson & Johnson 90

1.6.1 Overview 90

1.7 AbbVie Inc. 91

1.7.1 Overview 91

2 Annexure 94

Abbreviations 94

?


List Of Figure

Charts

 

CHART 1 RESEARCH METHODOLOGY OF GLOBAL AUTOINJECTOR MARKET 15

CHART 2 GLOBAL AUTOINJECTORS MARKET REVENUE, 2017-2024 (USD MILLION) 18

CHART 3 SEGMENTATION OF GLOBAL AUTOINJECTOR MARKET 23

CHART 4 PORTER 5 FORCES OF GLOBAL AUTOINJECTOR MARKET 24

CHART 5 PEST ANALYSIS OF AUTOINJECTOR MARKET 26

CHART 6 MARKET DYNAMICS-DRO ANALYSIS 27

CHART 7 DRO-IMPACT ANALYSIS OF GLOBAL AUTOINJECTORS MARKET 32

CHART 8 KEY STAKEHOLDERS 33

CHART 9 AUTOINJECTOR MARKET SEGMENT REVENUE BY APPLICATION, 2017 VS 2024 (USD MILLION) 34

CHART 10 ANAPHYLAXIS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 (USD MILLION) 36

CHART 11 MULTIPLE SCLEROSIS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 (USD MILLION) 36

CHART 12 RHEUMATOID ARTHRITIS MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 (USD MILLION) 37

CHART 13 DIABETES AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION 2017-2024 (USD MILLION) 39

CHART 14 OTHERS AUTOINJECTOR MARKET REVENUE, BY APPLICATION SEGMENTATION, 2017-2024 (USD MILLION) 40

CHART 15 AUTOINJECTOS MARKET SEGMENT SHARE BY TYPE SEGMENTATION, 2017 (%) 41

CHART 16 DISPOSSABLE AUTOINJECTOR MARKET REVENUE, 2017-2024 (USD MILLION) 42

CHART 17 REUSABLE AUTOINJECTORS MARKET REVENUE, 2017-2024 (USD MILLION) 43

CHART 18 AUTOINJECTOR MARKET BY REGIONAL SEGMENTATION, 2017 (%) 44

CHART 19 AUTOINJECTORS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 46

CHART 20 AUTOINJECTOR MARKET REVENUE IN EUROPE, 2017-2024 (USD MILLION) 47

CHART 21 AUTOINJECTORS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 (USD MILLION) 48

CHART 22 AUTO INJECTOR MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 49

CHART 23 AMGEN INC.: OVERVIEW SNAPSHOT 54

CHART 24 AMGEN INC.: GEOGRAPHIC PRESENCE 55

CHART 25 AMGEN INC.: SWOT ANALYSIS 57

CHART 26 BECTON DICKINSON AND COMPANY: OVERVIEW SNAPSHOT 60

CHART 27 BECTON DICKINSON AND COMPANY: BUSINESS UNITS 61

CHART 28 BECTON DICKINSON AND COMPANY: GEOGRAPHIC REVENUE 62

CHART 29 BECTON DICKINSON AND COMPANY: SWOT ANALYSIS 62

CHART 30 MYLAN N.V.: OVERVIEW SNAPSHOT 64

CHART 31 MYLAN N.V.: BUSINESS SEGMENTS 65

CHART 32 MYLAN N.V.: GEOGRAPHIC PRESENCE 67

CHART 33 MYLAN N.V.: SWOT ANALYSIS 67

CHART 34 BAYER AG: OVERVIEW SNAPSHOT 69

CHART 35 BAYER AG: BUSINESS UNITS 70

CHART 36 BAYER AG: GEOGRAPHICAL PRESENCE 71

CHART 37 BAYER AG: SWOT ANALYSIS 72

CHART 38 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 74

CHART 39 ELI LILLY & COMPANY LTD.: BUSINESS UNITS 75

CHART 40 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE 76

CHART 41 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS 76

CHART 42 NOVARTIS AG: OVERVIEW SNAPSHOT 78

CHART 43 NOVARTIS AG: BUSINESS UNITS 81

CHART 44 NOVARTIS AG: GEOGRAPHIC PRESENCE 81

CHART 45 NOVARTIS AG: SWOT ANALYSIS 82

 


List Of Table

Tables

 

TABLE 1 AUTOINJECTOR MARKET REVENUE BY APPLICATION SEGMENTATION, 2017-2024 (USD MILLION) 33

TABLE 2 PREVALENCE OF DIABETES POPULATION FORECASTING BY REGION 37

TABLE 3 AUTOINJECTOR MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 44

TABLE 4 AMGEN INC.: OFFERINGS 51

TABLE 5 AMGEN INC.: RECENT DEVELOPMENTS 51

TABLE 6 BECTON DICKINSON AND COMPANY: OFFERINGS 58

TABLE 7 BECTON DICKINSON AND COMPANY: RECENT DEVELOPMENTS 58

TABLE 1 MYLAN N.V.: OFFERINGS 63

TABLE 2 MYLAN N.V.: RECENT DEVELOPMENTS 63

TABLE 3 BAYER AG: OFFERINGS 68

TABLE 4 BAYER AG: RECENT DEVELOPMENTS 68

TABLE 5 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 72

TABLE 6 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 73

TABLE 7 NOVARTIS AG: OFFERINGS 77

TABLE 8 NOVARTIS AG: RECENT DEVELOPMENTS 78

TABLE 9 YPSOMED HOLDING AG: SNAPSHOT 83

TABLE 10 YPSOMED HOLDING AG: RECENT DEVELOPMENTS 83

TABLE 11 BIOGEN PHARMACEUTICALS: OVERVIEW 84

TABLE 12 BIOGEN PHARMACEUTICALS: RECENT DEVELOPMENTS 84

TABLE 13 PFIZER INC. OVERVIEW 85

TABLE 14 PFIZER INC.: RECENT DEVELOPMENTS 86

TABLE 15 TEVA PHARMACEUTICAL INDUSTRIES LTD. OVERVIEW 87

TABLE 16 TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS 88

TABLE 17 ANTARES PHARMA, INC.: OVERVIEW 89

TABLE 18 ANTARES PHARMA, INC.: RECENT DEVELOPMENTS 89

TABLE 19 JOHNSON & JOHNSON: OVERVIEW 90

TABLE 20 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 90

TABLE 21 ABBVIE INC.: OVERVIEW 91

TABLE 22 ABBVIE INC.: RECENT DEVELOPMENTS 92

 

 

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Mylan NV

Novartis AG

Amgen, Inc.

Becton Dickinson and Company

Bayer AG

Eli Lilly & Company Ltd Ypsomed Holding AG, Biogen Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical, Antares Pharma, Inc., Johnson and Johnson, and AbbVie Inc